These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 38453593)
1. Conversion From Immediate-Release to Prolonged-Release Tacrolimus in Kidney Transplant Patients With Tremor: A Case Series Study. Kamińska D; Hożejowski R; Chamienia A; Dębska-Ślizień A; Idasiak-Piechocka I; Oko A; Baranowicz-Gąszczyk I; Załuska W; Mazanowska O; Krajewska M Transplant Proc; 2024 May; 56(4):776-780. PubMed ID: 38453593 [TBL] [Abstract][Full Text] [Related]
2. Impact of Switching From Immediate- or Prolonged-Release to Once-Daily Extended-Release Tacrolimus (LCPT) on Tremor in Stable Kidney Transplant Recipients: The Observational ELIT Study. Giral M; Grimbert P; Morin B; Bouvier N; Buchler M; Dantal J; Garrigue V; Bertrand D; Kamar N; Malvezzi P; Moreau K; Athea Y; Le Meur Y Transpl Int; 2024; 37():11571. PubMed ID: 38694490 [TBL] [Abstract][Full Text] [Related]
3. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K; Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860 [TBL] [Abstract][Full Text] [Related]
4. Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study. Langone A; Steinberg SM; Gedaly R; Chan LK; Shah T; Sethi KD; Nigro V; Morgan JC; Clin Transplant; 2015 Sep; 29(9):796-805. PubMed ID: 26113208 [TBL] [Abstract][Full Text] [Related]
5. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients. Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study. Kamar N; Cassuto E; Piotti G; Govoni M; Ciurlia G; Geraci S; Poli G; Nicolini G; Mariat C; Essig M; Malvezzi P; Le Meur Y; Garrigue V; Del Bello A; Rostaing L Adv Ther; 2019 Feb; 36(2):462-477. PubMed ID: 30552587 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Once-Daily LCP-Tacrolimus Versus Twice-Daily Immediate-Release Tacrolimus in Adult Hispanic Stable Kidney Transplant Recipients: Sub-Group Analysis from a Phase 3 Trial. Faravardeh A; Akkina S; Villicana R; Guerra G; Moten MA; Meier-Kriesche U; Stevens DR; Patel SJ; Bunnapradist S Ann Transplant; 2021 Apr; 26():e929535. PubMed ID: 33859155 [TBL] [Abstract][Full Text] [Related]
8. Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial. Suwelack B; Bunnapradist S; Meier-Kriesche U; Stevens DR; Procaccianti C; Morganti R; Budde K Ann Transplant; 2020 Jul; 25():e923278. PubMed ID: 32719307 [TBL] [Abstract][Full Text] [Related]
9. Prolonged-Release Once-Daily Formulation of Tacrolimus Versus Standard-of-Care Tacrolimus in Budde K; Rostaing L; Maggiore U; Piotti G; Surace D; Geraci S; Procaccianti C; Nicolini G; Witzke O; Kamar N; Albano L; Büchler M; Pascual J; Gutiérrez-Dalmau A; Kuypers D; Wekerle T; Głyda M; Carmellini M; Tisone G; Midtvedt K; Wennberg L; Grinyó JM Transpl Int; 2022; 35():10225. PubMed ID: 36017158 [No Abstract] [Full Text] [Related]
10. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant. DuBay DA; Teperman L; Ueda K; Silverman A; Chapman W; Alsina AE; Tyler C; Stevens DR Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of the conversion to MeltDose Sánchez Fructuoso A; Ruiz JC; Franco A; Diekmann F; Redondo D; Calviño J; Serra N; Aladrén MJ; Cigarrán S; Manonelles A; Ramos A; Gómez G; González Posada JM; Andrés A; Beneyto I; Muñiz AL; Perelló M; Lauzurica R Clin Transplant; 2020 Jan; 34(1):e13767. PubMed ID: 31815310 [TBL] [Abstract][Full Text] [Related]
12. Early outcomes associated with de novo once-daily extended-release versus twice-daily immediate-release tacrolimus in a predominantly African American kidney transplant population: A single-center observational study. Romine MM; Leeser DB; Kennamer K; Nguyen C; Jones H; McLawhorn K; Kendrick S; Irish W Clin Transplant; 2024 Mar; 38(3):e15268. PubMed ID: 38450751 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients. Hurwitz JT; Grizzle AJ; Tyler CS; Zapata LV; Malone DC J Manag Care Spec Pharm; 2021 Jul; 27(7):948-960. PubMed ID: 34185556 [No Abstract] [Full Text] [Related]
14. Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients. Ruangkanchanasetr P; Sanohdontree N; Supaporn T; Sathavarodom N; Satirapoj B Ann Transplant; 2016 Dec; 21():765-774. PubMed ID: 27980321 [TBL] [Abstract][Full Text] [Related]
15. The use of LCP-Tacrolimus (Envarsus XR) in simultaneous pancreas and kidney (SPK) transplant recipients. Torabi J; Konicki A; Rocca JP; Ajaimy M; Campbell A; Azzi Y; Pynadath C; Liriano-Ward L; Akalin E; Kinkhabwala M; Graham JA Am J Surg; 2020 Apr; 219(4):583-586. PubMed ID: 32122660 [TBL] [Abstract][Full Text] [Related]
16. Conversion from Prograf to Advagraf in stable kidney transplant recipients: better renal function after 3-year follow-up. Spagnoletti G; Gargiulo A; Salerno MP; Favi E; Pedroso JA; Calia R; Romagnoli J; Citterio F Transplant Proc; 2014 Sep; 46(7):2224-7. PubMed ID: 25242756 [TBL] [Abstract][Full Text] [Related]
17. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation. Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809 [TBL] [Abstract][Full Text] [Related]
18. Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden. Fellström B; Holmdahl J; Sundvall N; Cockburn E; Kilany S; Wennberg L Transplant Proc; 2018 Dec; 50(10):3275-3282. PubMed ID: 30577197 [TBL] [Abstract][Full Text] [Related]
19. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups. Bunnapradist S; Rostaing L; Alloway RR; West-Thielke P; Denny J; Mulgaonkar S; Budde K Transpl Int; 2016 May; 29(5):603-11. PubMed ID: 26953629 [TBL] [Abstract][Full Text] [Related]